194 related articles for article (PubMed ID: 36003768)
1. Case Report: Efficacy of ensartinib treatment in pulmonary inflammatory myofibroblastic tumor with a rare
He W; Ji X; Song C; Song S; Liu L
Front Oncol; 2022; 12():934887. PubMed ID: 36003768
[TBL] [Abstract][Full Text] [Related]
2. Case report: Epithelioid inflammatory myofibroblastic sarcoma treated with an ALK TKI ensartinib.
Li M; Xing R; Huang J; Shi C; Wei C; Wang H
Front Oncol; 2023; 13():1084456. PubMed ID: 37035183
[TBL] [Abstract][Full Text] [Related]
3. Case Report: Ensartinib for gastric epithelioid inflammatory myofibrosarcoma with STRN-ALK fusion.
Li X; Zheng J; Li X; Chen Y; Liu K; Li F; Lu Z
Front Oncol; 2023; 13():1252221. PubMed ID: 37869075
[TBL] [Abstract][Full Text] [Related]
4. GCC2-ALK as a targetable fusion in lung adenocarcinoma and its enduring clinical responses to ALK inhibitors.
Jiang J; Wu X; Tong X; Wei W; Chen A; Wang X; Shao YW; Huang J
Lung Cancer; 2018 Jan; 115():5-11. PubMed ID: 29290262
[TBL] [Abstract][Full Text] [Related]
5. Durable Clinical Response to ALK Tyrosine Kinase Inhibitors in Epithelioid Inflammatory Myofibroblastic Sarcoma Harboring
Wang Z; Geng Y; Yuan LY; Wang MM; Ye CY; Sun L; Dai WP; Zang YS
Front Oncol; 2022; 12():761558. PubMed ID: 35237506
[TBL] [Abstract][Full Text] [Related]
6. Two cases of inflammatory myofibroblastic tumor treated with targeted drugs: A case report.
Liu M; Zhu D
Medicine (Baltimore); 2024 May; 103(21):e38136. PubMed ID: 38787978
[TBL] [Abstract][Full Text] [Related]
7. Inflammatory myofibroblastic tumor of the urinary bladder with FN1‑ALK gene fusion: A case report.
Son SM; Woo CG; Lee OJ; Kim YJ; Lee HC
Oncol Lett; 2023 Jun; 25(6):227. PubMed ID: 37153035
[TBL] [Abstract][Full Text] [Related]
8. Case Report: Clinical response to anaplastic lymphoma kinase inhibitor-based targeted therapy in uterine inflammatory myofibroblastic tumor harboring
Zhao T; Zhang X; Liu X; Ren M; Cheng Y; Wang J; Luo Z
Front Oncol; 2023; 13():1147974. PubMed ID: 37035208
[TBL] [Abstract][Full Text] [Related]
9. A recurrent inflammatory myofibroblastic tumor patient with two novel
Xu X; Li L; Zhang Y; Meng F; Xie H; Duan R
Transl Cancer Res; 2022 Sep; 11(9):3379-3384. PubMed ID: 36237256
[TBL] [Abstract][Full Text] [Related]
10. Rare
Qin J; Zeng D; Xie F; Yu R; Wu X; Liu K; Shao YW; Lu H; Jiang J
Transl Cancer Res; 2019 Sep; 8(5):2187-2191. PubMed ID: 35116968
[TBL] [Abstract][Full Text] [Related]
11. Case Report: Early Distant Metastatic Inflammatory Myofibroblastic Tumor Harboring
Han Q; He X; Cui L; Qiu Y; Li Y; Chen H; Zhang H
Front Med (Lausanne); 2022; 9():826705. PubMed ID: 35280868
[TBL] [Abstract][Full Text] [Related]
12. Mixed responses to first-line alectinib in non-small cell lung cancer patients with rare ALK gene fusions: A case series and literature review.
Li M; An Z; Tang Q; Ma Y; Yan J; Chen S; Wang Y
J Cell Mol Med; 2021 Oct; 25(19):9476-9481. PubMed ID: 34541785
[TBL] [Abstract][Full Text] [Related]
13. Locally Advanced Inflammatory Myofibroblastic Tumor Treated With Targeted Therapy: A Case Report and Literature Review.
Durham C; Clemons M; Alias A; Konduri K
Cureus; 2022 Jul; 14(7):e27223. PubMed ID: 36035049
[TBL] [Abstract][Full Text] [Related]
14. Intraosseous inflammatory myofibroblastic tumor of the mandible with a novel ATIC-ALK fusion mutation: a case report.
Tateishi Y; Okudela K; Kawai S; Suzuki T; Umeda S; Matsumura M; Kioi M; Ohashi K
Diagn Pathol; 2016 Nov; 11(1):132. PubMed ID: 27846861
[TBL] [Abstract][Full Text] [Related]
15. Case Report: A rare case of non-small cell lung cancer with STRN-ALK fusion in a patient in very poor condition treated with first-line ensartinib.
Song GQ; Li YZ; Kong W; Hu GQ
Front Oncol; 2023; 13():1235679. PubMed ID: 37810968
[TBL] [Abstract][Full Text] [Related]
16. Inflammatory Myofibroblastic Tumor Driven by Novel
Rao N; Iwenofu H; Tang B; Woyach J; Liebner DA
J Natl Compr Canc Netw; 2018 Feb; 16(2):115-121. PubMed ID: 29439172
[TBL] [Abstract][Full Text] [Related]
17. Ensartinib vs Crizotinib for Patients With Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: A Randomized Clinical Trial.
Horn L; Wang Z; Wu G; Poddubskaya E; Mok T; Reck M; Wakelee H; Chiappori AA; Lee DH; Breder V; Orlov S; Cicin I; Cheng Y; Liu Y; Fan Y; Whisenant JG; Zhou Y; Oertel V; Harrow K; Liang C; Mao L; Selvaggi G; Wu YL
JAMA Oncol; 2021 Nov; 7(11):1617-1625. PubMed ID: 34473194
[TBL] [Abstract][Full Text] [Related]
18. A novel LRRFIP1-ALK fusion in inflammatory myofibroblastic tumor of hip and response to crizotinib.
Liu W; Duan Q; Gong L; Yang Y; Huang Z; Guo H; Niu X
Invest New Drugs; 2021 Feb; 39(1):278-282. PubMed ID: 32915420
[TBL] [Abstract][Full Text] [Related]
19. [Expert consensus on ensartinib in the treatment of anaplastic lymphoma kinase-positive non-small cell lung cancer].
Zhang L; Yang YP; ;
Zhonghua Zhong Liu Za Zhi; 2022 Apr; 44(4):297-307. PubMed ID: 35448917
[TBL] [Abstract][Full Text] [Related]
20. Primary inflammatory myofibroblastic tumour of the liver: a clinicopathological and genetic study including a subset with ETV6::NTRK3 fusion.
Han Q; Zhang Z; He X; Chen M; Pang X; Chen C; Du T; Zhang H
Histopathology; 2023 May; 82(6):925-936. PubMed ID: 36748182
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
